Downloadable Publications



Vascular regulation of antitumor immunity

Immunotherapy with immune checkpoint blockers (ICBs) has revolutionized cancer treatment. Unfortunately, ICB therapy usually benefits <15% of patients and causes immune-related adverse events in a substantial number of patients. Another immunotherapy—engineered chimeric antigen receptor (CAR) T cells that specifically target tumor-associated antigens—has transformed the treatment of multiple hematological cancers and exhibited therapeutic potential in solid tumors. Emerging data show that the function of blood vessels associated with tumors is critical in the response to these immunotherapies.

Full Text Link: Science Full Text

Reprint: Science Reprint



Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial

What is the effect of an induction chemotherapy treatment with aflibercept plus a modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) followed by standard chemoradiotherapy and total mesorectal excision surgery in patients with magnetic resonance imaging–defined high-risk, locally advanced rectal adenocarcinoma?

Free article access: JAMA Oncology


Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges

J.D. Martin, G. Seano, R.K. Jain

Abnormal blood and lymphatic vessels create a hostile tumor microenvironment characterized by hypoxia, low pH, and elevated interstitial fluid pressure. These abnormalities fuel tumor progression, immunosuppression, and treatment resistance. In 2001, we proposed a novel hypothesis that the judicious use of antiangiogenesis agents—originally developed to starve tumors—could transiently normalize tumor vessels and improve the outcome of anticancer drugs administered during the window of normalization. In addition to providing preclinical and clinical evidence in support of this hypothesis, we also revealed the underlying molecular mechanisms. In parallel, we demonstrated that desmoplasia could also impair vascular function by compressing vessels, and that normalizing the extracellular matrix could improve vascular function and treatment outcome in both preclinical and clinical settings. Here, we summarize the progress made in understanding and applying the normalization concept to cancer and outline opportunities and challenges ahead to improve patient outcomes using various normalizing strategies.

Free article access: annualreviews.org/eprint/

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer

Vasileios Askoxylakis, Gino B Ferraro, Mark Badeaux, David P Kodack, Isabelle Kirst, Ram C Shankaraiah, Christina S F Wong, Dan G Duda, Dai Fukumura, and Rakesh K Jain.

The effective treatment of cerebral metastases from HER2-positive breast cancer remains an unmet need. Recent studies indicate that activated astrocytes and brain endothelial cells exert chemoprotective effects on cancer cells through direct physical interaction. Here we report that the endothelin axis mediates protection of HER2-amplified brain metastatic breast cancers to the anti-HER2 antibody–drug conjugate ado-trastuzumab emtansine (T-DM1). Macitentan, a dual inhibitor of endothelin receptors A and B, improves the efficacy of T-DM1 against breast cancers grown in the brain. We show that direct contact of brain stroma with cancer cells is required for protection to T-DM1. Our data suggest that targeting the endothelin axis may be beneficial when anti-signaling agent and cytotoxic agent are combined. These findings may contribute to the development of therapeutic approaches with enhanced efficacy in the brain microenvironment..

Free article access: https://rdcu.be/bgVG5

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium

Giorgio Seano, Hadi T Nia, Kyrre E Emblem, Meenal Datta, Jun Ren, Shanmugarajan Krishnan, Jonas Kloepper, Marco C Pinho, William W Ho, Mitrajit Ghosh, Vasileios Askoxylakis, Gino B Ferraro, Lars Riedemann, Elizabeth R Gerstner, Tracy T Batchelor, Patrick Y Wen, Nancy U Lin, Alan J Grodzinsky, Dai Fukumura, Peigen Huang, James W Baish, Timothy P Padera, Lance L Munn, and Rakesh K Jain

The compression of brain tissue by a tumour mass is believed to be a major cause of the clinical symptoms seen in patients with brain cancer. However, the biological consequences of these physical stresses on brain tissue are unknown. Here, via imaging studies in patients and by using mouse models of human brain tumours, we show that a subgroup of primary and metastatic brain tumours, classified as nodular on the basis of their growth pattern, exert solid stress on the surrounding brain tissue, causing a decrease in local vascular perfusion as well as neuronal death and impaired function. We demonstrate a causal link between solid stress and neurological dysfunction by applying and removing cerebral compression, which respectively mimic the mechanics of tumour growth and of surgical resection. We also show that, in mice, treatment with lithium reduces solid-stress-induced neuronal death and improves motor coordination. Our findings indicate that brain-tumour-generated solid stress impairs neurological function in patients, and that lithium as a therapeutic intervention could counter these effects

Free article access: https://rdcu.be/wf

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M Luisa Iruela-Arispe, Claire E Lewis, Lisa M Coussens, Aditya Bardia, Rakesh K Jain, Jeffrey W Pollard, and Michele De Palma

Taxanes and anthracyclines elicit EVs that enhance metastasis

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can facilitate the seeding and growth of metastatic cancer cells in distant organs, but the effects of chemotherapy on tumour-derived EVs remain unclear. Here we show that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs with enhanced pro-metastatic capacity. Chemotherapy-elicited EVs are enriched in annexin A6 (ANXA6), a Ca2+-dependent protein that promotes NF-κB-dependent endothelial cell activation, Ccl2 induction and Ly6C+CCR2+ monocyte expansion in the pulmonary pre-metastatic niche to facilitate the establishment of lung metastasis. Genetic inactivation of Anxa6 in cancer cells or Ccr2 in host cells blunts the pro-metastatic effects of chemotherapy-elicited EVs. ANXA6 is detected, and potentially enriched, in the circulating EVs of breast cancer patients undergoing neoadjuvant chemotherapy.

Free article access: https://rdcu.be/be4fa


Quantifying solid stress and elastic energy from excised or in situ tumors. 

Nia HT, Datta M, Seano G, Huang, P, Munn LL, Jain RK.

Measuring Solid Stress

Solid stress, distinct from both tissue stiffness and fluid pressure, is a mechanical stress that is often elevated in both murine and human tumors. The importance of solid stress in tumor biology has been recognized in initial studies: solid stress promotes tumor progression and lowers the efficacy of anticancer therapies by compressing blood vessels and contributing to hypoxia. However, robust, reproducible, and objective methods that go beyond demonstration and bulk measurements have not yet been established. We have developed three new techniques to rigorously measure and map solid stress in both human and murine tumors that are able to account for heterogeneity in the tumor microenvironment.

Free article access: https://rdcu.be/LZEV


Methicillin-resistant Staphylococcus aureus causes sustained collecting lymphatic vessel dysfunction

Dennis Jones, Eelco F. J. Meijer, Cedric Blatter, Shan Liao, Ethel R. Pereira, Echoe M. Bouta, Keehoon Jung, Shan Min Chin, Peigen Huang, Lance L. Munn, Benjamin J. Vakoc, Michael Otto, Timothy P. Padera

Lymphatics limp along after MRSA

Lymphedema is associated with skin and soft tissue infections, and both can be recurring, causing continual suffering in affected patients. To better understand the relationship between bacterial infections and lymphedema, Jones et al. used intravital imaging to examine the lymphatics of mice infected with MRSA. They observed lymphatic muscle cell death, which led to prolonged dysfunction months after the bacteria had been cleared. In vitro experiments with human cells indicated that bacterial toxins were responsible for damaging the lymphatic muscle cells, suggesting that the toxins could be targeted in patients to interrupt this brutal cycle.

Abstract: http://stm.sciencemag.org/cgi/content/abstract/10/424/eaam7964?ijkey=NKnCrZHv0SPVU&keytype=ref&siteid=scitransmed

Reprint: http://stm.sciencemag.org/cgi/rapidpdf/10/424/eaam7964?ijkey=NKnCrZHv0SPVU&keytype=ref&siteid=scitransmed

Full text: http://stm.sciencemag.org/cgi/content/full/10/424/eaam7964?ijkey=NKnCrZHv0SPVU&keytype=ref&siteid=scitransmed


Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Joao Incio, Jennifer A. Ligibel, Daniel T. McManus, Priya Suboj, Keehoon Jung, Kosuke Kawaguchi, Matthias Pinter, Suboj Babykutty, Shan M. Chin, Trupti D. Vardam, Yuhui Huang, Nuh N. Rahbari, Sylvie Roberge, Dannie Wang, Igor L. Gomes-Santos, Stefan B. Puchner9, Christopher L. Schlett, Udo Hoffmman, Marek Ancukiewicz1, Sara M. Tolaney, Ian E. Krop, Dan G. Duda, Yves Boucher, Dai Fukumura, and Rakesh K. Jain

Tailored treatment for cancer in obesity

Antiangiogenic therapy with inhibitors of the vascular endothelial growth factor (VEGF) has not proven effective in patients with many tumor types, including breast cancer. Meanwhile, obesity is a well-known risk factor in many cancer types, and once again, this includes breast cancer. Now, Incio et al. link these two observations, having discovered a mechanism by which obesity promotes resistance to VEGF inhibitor therapy through increased interleukin-6 and possibly also fibroblast growth factor 2 in the tumor microenvironment. The authors target these pathways in mouse models of cancer with and without obesity and demonstrate that the deleterious effects of obesity on VEGF inhibition can be overcome through the appropriate combination therapy.

Abstract:  http://stm.sciencemag.org/cgi/content/abstract/10/432/eaag0945?ijkey=V1yFKy8ChLxDk&keytype=ref&siteid=scitransmed

Reprint:  http://stm.sciencemag.org/cgi/rapidpdf/10/432/eaag0945?ijkey=V1yFKy8ChLxDk&keytype=ref&siteid=scitransmed

Full text:  http://stm.sciencemag.org/cgi/content/full/10/432/eaag0945?ijkey=V1yFKy8ChLxDk&keytype=ref&siteid=scitransmed